NCT04501939View on ClinicalTrials.gov

Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 6, 2020

Primary Completion Date

July 22, 2026

Study Completion Date

July 22, 2026

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Cirmtuzumab

Cycle 1, Day 1 \& 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg

DRUG

Venetoclax

Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.

Trial Locations (1)

92037

UCSD Koman Family Outpatient Pavilion, San Diego

Sponsors
All Listed Sponsors
collaborator

Oncternal Therapeutics, Inc

INDUSTRY

lead

University of California, San Diego

OTHER

NCT04501939 - Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax | Biotech Hunter | Biotech Hunter